Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet AMD).
- GB-102 is a proprietary formulation of sunitinib malate injected twice a year intravitreally.
- The ALTISSIMO full-data analysis focused on the GB-102 1mg arm compared to aflibercept and the pre-enrollment period, excluding results from the GB-102 2mg arm.
- Overall, GB-102 1mg was safe and well-tolerated. No drug-related serious adverse events or vision-threatening inflammation were reported.
- The majority of drug-related adverse events were mild to moderate. The particle migration to the anterior chamber in patients treated with GB-102 1mg was reduced by 79% compared to GB-102 1mg patients in the ADAGIO Phase 1/2a trial (4/51 injections vs. 3/8), and no surgical interventions were required.
- As previously reported, patients in the GB-102 1mg trial arm (n=21) had a median time to first supportive therapy of five months, and 48% of patients did not require supportive treatment for at least six months.
- An additional analysis showed the injection frequency was reduced by 58% compared to patients' treatment before enrollment in the trial.
- The company is also working on a GB-401 implant program for glaucoma that will enter a Phase 1 trial in the first half of 2022.
- Graybug expects to report the results from the ongoing six-month extension period of ALTISSIMO by the end of this year.
- The company also said it would pause developing GB-103 and GB-102 for diabetic macular edema and utilize the cash to advancing GB-401 through Phase 1 clinical development.
- The company's management will host a webcast and conference call at 8 a.m. ET today to discuss the ALTISSIMO clinical results.
- Price Action: GRAY shares are trading 7.4% lower at $4.38 on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!